takes place. thank you very much forjoining me. welcome to our viewers on pbs in america and around the globe. let s start with the astrazeneca vaccine. the european medicines agency has been examining its safety after more than a dozen eu members suspended it this week over health concerns. and today, we heard its verdict. the committee has come to a clear scientific conclusion. this is a safe and effective vaccine. its benefits in protecting people from covid i9 with the associated risks of death and hospitalisation outweigh the possible risks. the committee also concluded that the vaccine is not associated with an increase in the overall risk of thromboembolic events or blood clots. that press conference took place in amsterdam, and our correspondent jean mackenzie was there. what they ve been saying all along stands, that they think this is a vaccine in which the benefits massively outweigh the risks. it was striking, they pointed out there how many people have died in th
december before we were sworn in to an average of 2.5 million shots a day. when he took office, they were almost at 1 million shots a day, we should note. right now, 12% of the population is fully vaccinated. experts estimate we need that number to be 70 to 85% in order for the u.s. to achieve something like herd immunity. the president is also still standing by his promise of enough vaccine supply for every american adult by the end of may. those life-saving vaccines could not come soon enough. progress in bringing down coronavirus cases are stalling. more states in the u.s. are seeing cases on the rise right now than a decline in new infections. and president biden is warning against dangerous variants of the virus. also today, some major news that could likely mean more children in classrooms sooner. an official tells cnn that the cdc is expected to update its guidance for physical distancing in schools tomorrow, changing the guidelines from six feet of distancing to thr
Study results presented at the 2023 American Society of Hematology Annual Meeting and Exposition found equal immune tolerance induction success rates regardless of race/ethnicity.